Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

Start Date20 Mar 2024

Sponsor / Collaborator

Bayer AG

[+3]

NCT05688436

/ RecruitingNot Applicable

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

The primary objective of the study is to estimate the prevalence of major congenital malformations (MCMs) and compare the prevalence between the diroximel fumarate (DRF) and comparator groups. The secondary objectives of the study are to estimate the incidence of spontaneous abortion (SA) and compare the incidence between the DRF and comparator groups; to estimate the incidence of preterm birth and compare the incidence between the DRF and comparator groups; to estimate the incidence of stillbirth and compare the incidence between the DRF and comparator groups and to estimate the prevalence of small for gestational age (SGA) and compare the prevalence between the DRF and comparator groups.

Start Date24 Sep 2021

Sponsor / Collaborator

Biogen, Inc.

NCT04967430

/ Unknown statusPhase 3IIT

TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Interferon (IFN) lambda is one of the fundamental responses of the innate immune system. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming it safety and tolerability. It is particularly attractive for consideration in the use of acute respiratory illness due to the high expression of the lambda receptor in lung epithelia. We propose to evaluate peginterferon-lambda in ambulatory patients with mild to moderate COVID-19.

Start Date27 Aug 2021

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Peginterferon Beta-1a

100 Translational Medicine associated with Peginterferon Beta-1a

100 Patents (Medical) associated with Peginterferon Beta-1a

104

Literatures (Medical) associated with Peginterferon Beta-1a

01 Feb 2025·Multiple Sclerosis and Related Disorders

Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies

Review

Author: Brzostek, Tomasz ; Moćko, Paweł ; Śladowska, Katarzyna ; Kawalec, Paweł

OBJECTIVE:

This study aimed to review the efficacy and safety profile of disease-modifying therapies (DMTs) in patients with relapsing pediatric-onset multiple sclerosis (POMS).

METHODS:

A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Published randomized controlled trials (RCTs), nonrandomized studies with a control group, large single-arm studies, and ongoing (unpublished) studies investigating the use of approved and unapproved DMTs in POMS were included. Eligible published studies were identified in MEDLINE (via PubMed), EMBASE, and the Cochrane Library, and unpublished studies were identified in a clinical trials registry (www.

CLINICALTRIALS:

gov).

RESULTS:

A total of 13 published studies were included in the systematic review: 4 RCTs, 3 observational studies with a control group, and 6 large single-arm studies. The following DMTs for the treatment of POMS were evaluated in the included studies: interferon beta-1a, interferon beta-1b, teriflunomide, dimethyl fumarate, fingolimod, natalizumab, glatiramer acetate, and ocrelizumab. All DMTs were shown to be effective in reducing relapse rates, preventing disability progression, and reducing disease activity in MRI in patients with POMS. DMTs that are considered highly effective in adults with multiple sclerosis (natalizumab, fingolimod) were also shown to be more effective than interferon beta-1a in POMS. A total of 9 ongoing (unpublished) studies were identified, including 5 RCTs. The following drugs were evaluated: ozanimod, fingolimod, peginterferon beta-1a, ocrelizumab, ofatumumab, siponimod, alemtuzumab, and natalizumab.

CONCLUSION:

The number of DMTs approved for the treatment of POMS is limited, and some of the available DMTs are used off-label. The available evidence from published studies of varying reliability supports the efficacy of DMTs in POMS. However, well-designed, long-term RCTs in the pediatric population are needed. The results of ongoing studies may fill the existing gap in clinical evidence, possibly leading to the approval of more highly effective DMTs for patients with POMS.

01 Oct 2024·Multiple Sclerosis and Related Disorders

Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)

Article

Author: Saeidi, Morteza ; Ghiasian, Masoud ; Baghbanian, Seyed Mohammad ; Abolfazli, Roya ; Ayromlou, Hormoz ; Ghalyanchi Langroodi, Hamidreza ; Asadollahzadeh, Elnaz ; Shaygannejad, Vahid ; Beladi Moghadam, Nahid ; Sabzvari, Araz ; Ashtari, Fereshteh ; Kafi, Hamidreza ; Azimi Saeen, Amirreza

BACKGROUND:

Multiple sclerosis (MS) is a prevalent, disabling, inflammatory, neurodegenerative disease that typically manifests during a highly productive stage of life. Interferon beta-1a was among the first approved disease-modifying therapies for MS and remains among the first-line treatment options. Pegylation of the interferon beta-1a molecule prolongs its half-life while maintaining its efficacy and safety profile. In PEGINTEGRITY study, we aimed to compare peginterferon beta-1a with interferon beta-1a in terms of efficacy and safety in relapsing-remitting multiple sclerosis (RRMS) patients.

METHODS:

This study was a randomized, active-controlled, parallel-group, multi-center Phase 3 trial conducted in Iran in participants with RRMS. Participants received 125 µg of subcutaneous peginterferon beta-1a every two weeks or 30 µg of intramuscular interferon beta-1a once a week for up to 96 weeks. The primary outcome was the non-inferiority of peginterferon beta-1a to interferon beta-1a in reducing annualized relapse rate (ARR). Other outcomes included the number of patients with 12-week confirmed disability progression, the number of new or newly-enlarging T2 hyperintense lesions, the number of gadolinium-enhancing lesions, the number of new T1 hypointense lesions, the volume of new or newly-enlarging T2 hyperintense lesions, changes in brain volume, immunogenicity, and safety assessments.

RESULTS:

A total of 168 patients who met the eligibility criteria were enrolled and assigned to two arms of the study, each consisting of 84 participants. Totally, 41 participants (24 patients in the peginterferon beta-1a group and 17 patients in the interferon beta-1a group) were withdrawn from the study. The withdrawn patients were included in the per-protocol analysis for the period of time they were in the study. In 96 weeks, in the per-protocol population, the ARR was 0.05 in the peginterferon beta-1a group versus 0.11 in the interferon beta-1a group, which does not reflect a statistically significant difference (p=0.09; 95 % CI, 0.18-1.14). Considering the upper limit of the one-sided 95 % CI of the rate ratio of peginterferon beta-1a compared to interferon beta-1a, as well as the non-inferiority margin, it can be concluded that the primary outcome was met. The results were also comparable for other efficacy and safety outcomes.

CONCLUSION:

The results demonstrate the non-inferiority of peginterferon beta-1a to interferon beta-1a with similar efficacy in 96-week ARR in RRMS patients. Both arms were also comparable in other efficacy outcomes and safety profiles with no statistically significant differences. These findings support considering peginterferon beta-1a as a safe and efficient option in patients with RRMS. This study was registered on Iranian Registry of Clinical Trials (IRCT201612306135N8) and clinicaltrials.gov (NCT05242133).

01 Apr 2024·Multiple Sclerosis Journal-Experimental Translational and Clinical

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program

Article

Author: Kumar, Achint ; Belviso, Nicholas ; Nelles, Gereon ; Koster, Thijs ; Salvetti, Marco ; Castro-Borrero, Wanda ; Wray, Sibyl ; Vignos, Megan

Background:

Interferon beta-1a remains an important treatment option for multiple sclerosis, particularly when safety or tolerability concerns may outweigh the benefits of higher-efficacy disease-modifying therapies. The five-year phase 4 Plegridy Observational Program (POP) study (NCT02230969) collected data on real-world safety and effectiveness of Plegridy® (peginterferon beta-1a) treatment in patients with relapsing multiple sclerosis.

Objective:

To explore the real-world safety and effectiveness of peginterferon beta-1a in patients with relapsing multiple sclerosis, including factors influencing treatment discontinuation.

Methods:

Data were collected prospectively from patients ≥ 18 years old with relapsing multiple sclerosis for overall population analysis and for subpopulations including newly/previously diagnosed patients, age, and experience with peginterferon beta-1a. Outcome measures included annualized relapse rates, adverse events, and predictors of time to treatment discontinuation.

Results:

Mean (SD) treatment duration in the overall population ( N = 1172) was 896.0 (733.15) days. Incidence of adverse events was higher in new than experienced users (79.4% vs. 57.0%). New users were more likely than experienced users to discontinue (hazard ratio = 1.60; P < 0.0001). The adjusted annualized relapse rate was 0.09, and at the end of 5 years, 77.1% of patients were relapse-free.

Conclusions:

Peginterferon beta-1a is an effective therapy for managing relapsing multiple sclerosis. The identification of predictors of discontinuation can help inform strategies to enhance treatment persistence.

News (Medical) associated with Peginterferon Beta-1a

04 Apr 2024

·www.prnewswire.com

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

OKLAHOMA CITY, April 4, 2024 /PRNewswire/ -- Cadenza Bio, Inc., a pioneering preclinical biotechnology company dedicated to developing innovative small-molecule drugs for the treatment of multiple sclerosis (MS) and other demyelinating and inflammatory diseases, proudly announces the appointment of Michael A. Panzara, MD, MPH, to its esteemed board of directors. Dr. Panzara brings over 22 years of invaluable biopharmaceutical experience to Cadenza Bio. He currently serves as chief medical officer at Neurvati Neurosciences, a neuroscience-focused biotechnology company working to advance the development of clinical-stage product candidates for neurological and neuropsychiatric disorders. Prior to his role at Neurvati, Dr. Panzara held key leadership positions at Wave Life Sciences, Sanofi, Genzyme, and Biogen, showcasing his deep understanding of neurological disorders and drug development. He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company. Over his career, Dr. Panzara oversaw development activities and global regulatory approvals for several MS drugs. He served as the head of the Multiple Sclerosis, Neurology, and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he oversaw global regulatory approvals of LEMTRADA® (alemtuzumab) and AUBAGIO® (teriflunomide) and was responsible for development strategy and oversight within these therapeutic areas. During his time at Biogen, he served as global clinical lead for the development of TYSABRI® (natalizumab) for MS and managed clinical development activities for all late-stage MS products including AVONEX® (interferon beta-1a), PLEGRIDY® (PEG-interferon beta-1a), and TECFIDERA® (dimethylfumarate). "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, chief executive officer of Cadenza Bio. "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio. Dr. Panzara's strategic insights and deep understanding of the industry will be invaluable as we continue to advance our innovative drug pipeline and work towards bringing transformative treatments to patients in need." Dr. Panzara received his undergraduate degree in biology from the University of Pennsylvania and his medical degree from Stanford University School of Medicine. He completed his neurology training at Massachusetts General Hospital and received postdoctoral training in immunology and rheumatology at Brigham and Women's Hospital. Additionally, Dr. Panzara earned his master of public health degree from the Harvard School of Public Health. With Dr. Panzara joining the board of directors, Cadenza Bio is in a stronger position to achieve its goal of developing groundbreaking therapies for MS and other demyelinating and inflammatory diseases. "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara. "Their approach in developing innovative dual-action therapeutic agents with neuroprotective and immunomodulatory effects has great potential to significantly expand our ability to address the unmet needs that remain for many MS patients." For more information about Cadenza Bio and its groundbreaking research, please visit . About Cadenza Bio, Inc. Cadenza Bio, Inc. is a preclinical biotechnology company focused on developing innovative small-molecule drugs for the treatment of demyelinating and inflammatory diseases. The company's mission is to break the cycle of disease and transform lives by developing therapies that not only alleviate symptoms but also halt progression, promote repair, and restore quality of life for patients. Cadenza Bio's MS drug pipeline, emerging from a collaboration between leading researchers, demonstrates promising preclinical results and offers hope for patients suffering from these debilitating conditions. SOURCE Cadenza Bio, Inc.

Executive Change

03 Apr 2024

·www.pharmaindustrial-india.com

Cadenza Bio Welcomes Michael A. Panzara to its Board of Directors

Cadenza Bio, Inc. has appointed Michael A. Panzara, MD, MPH, to its esteemed board of directors. Dr. Panzara brings over 22 years of invaluable biopharmaceutical experience to Cadenza Bio. He currently serves as Chief Medical Officer at Neurvati Neurosciences, a neuroscience-focused biotechnology company working to advance the development of clinical-stage product candidates for neurological and neuropsychiatric disorders. Before his role at Neurvati, Dr. Panzara held key leadership positions at Wave Life Sciences, Sanofi, Genzyme, and Biogen, showcasing his deep understanding of neurological disorders and drug development. He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company. Over his career, Dr. Panzara oversaw development activities and global regulatory approvals for several MS drugs. He served as the head of the Multiple Sclerosis, Neurology, and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he oversaw global regulatory approvals of LEMTRADA (alemtuzumab) and AUBAGIO (teriflunomide) and was responsible for development strategy and oversight within these therapeutic areas. During his time at Biogen, he served as global clinical lead for the development of TYSABRI (natalizumab) for MS and managed clinical development activities for all late-stage MS products including AVONEX (interferon beta-1a), PLEGRIDY (PEG-interferon beta-1a), and TECFIDERA (dimethylfumarate). "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, Chief Executive Officer of Cadenza Bio. "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio. Dr. Panzara's strategic insights and deep understanding of the industry will be invaluable as we continue to advance our innovative drug pipeline and work towards bringing transformative treatments to patients in need," said Curtis. Dr. Panzara received his undergraduate degree in biology from the University of Pennsylvania and his medical degree from Stanford University School of Medicine. He completed his neurology training at Massachusetts General Hospital and received postdoctoral training in immunology and rheumatology at Brigham and Women's Hospital. Additionally, Dr. Panzara earned his master of public health degree from the Harvard School of Public Health. With Dr. Panzara joining the board of directors, Cadenza Bio is in a stronger position to achieve its goal of developing groundbreaking therapies for MS and other demyelinating and inflammatory diseases. "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara. "Their approach in developing innovative dual-action therapeutic agents with neuroprotective and immunomodulatory effects has great potential to significantly expand our ability to address the unmet needs that remain for many MS patients,” added Dr. Panzara.

Executive Change

10 Apr 2023

·www.biospace.com

In Another Round of Cuts, Biogen Lays Off Unspecified Number of Employees

Pictured: Biogen sign in front of an office building/courtesy of John Tlumacki/The Boston Globe via Getty Biogen is laying off an unspecified number of employees, according to a article published Monday by the Boston Business Journal. A Biogen spokesperson confirmed the layoffs in an email to BioSpace but declined to reveal the exact number of affected employees. In a LinkedIn post published in late March, Matt Winton, former senior vice president and head of the company’s U.S. multiple sclerosis franchise, announced that he was leaving Biogen. He wrote that he was proud of his team's work in the MS and SMA communities. Winton served Biogen for more than nine years. The Biogen spokesperson did not explicitly confirm to BioSpace whether the job cuts would primarily affect the company’s MS business. Christopher Viehbacher, president and CEO of Biogen, foreshadowed these job cuts in the company’s Q4 and full-year 2022 financial results presentation in February 2023, referring specifically to the “declining revenue base” of its MS business. Still, the company needs to be careful to “find the right balance” and not take too much from multiple sclerosis so as not to worsen already-declining sales, he said. For 2023, while Viehbacher expects to implement cost-reduction measures for its MS franchise, he said he anticipates some new investments, particularly as Biogen re-evaluates its general and administrative expenses for MS. The spokesperson said the MS franchise is an important part of Biogen’s base business and that the company would continue to invest as appropriate. “However, we will need to find the right balance across the entire portfolio to support the Leqembi and zuranolone launches [and] to sustain innovation in R&D," the spokesperson said. Monday’s layoffs follow a sweeping headcount reduction implemented throughout 2022 that saw the planned termination of as many as 1,000 employees. The cost-cutting initiative was meant to help Biogen recoup losses from the launch of its troubled Alzheimer’s medicine, Aduhelm. MS is Still Biogen’s Top Earner During the investor call, Viehbacher said the MS franchise still supports most of Biogen’s revenue. In 2022, Biogen’s MS business earned $5.43 billion dollars, accounting for nearly 68% of the company’s full-year revenue. Still, at constant currencies, MS sales dropped 9% from the year prior due to generic competition and pricing pressures. Of its MS assets, Tysabri (natalizumab) remains Biogen’s strongest seller, earning more than $2.3 billion in 2022. Approved in 2004, Tysabri is a monoclonal antibody that binds to T cells and prevents them from attacking nerves in the brain and spinal cord, a pathological hallmark of MS. Tecfidera (dimethyl fumarate), an activator of the Nrf2 pathway, is Biogen’s second-highest-selling MS asset, bringing in more than $1.4 billion in 2022. Tecfidera was approved in 2013. Biogen’s MS franchise also includes the fumarate-based oral drug Vumerity (diroximel fumarate), the interferon medicines Avonex (interferon beta-1a) and Plegridy (peginterferon beta-1a) and the oral drug Fampyra (fampridine), which is being marketed by Acorda Therapeutics as Ampyra in the U.S. Tristan Manalac is an independent science writer based in metro Manila, Philippines. He can be reached at tristan@tristanmanalac.com or tristan.manalac@biospace.com

Drug Approval

100 Deals associated with Peginterferon Beta-1a

External Link

KEGG	Wiki	ATC	Drug Bank
D10483	Peginterferon Beta-1a	L03AB13	DB09122

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	United States	Biogen, Inc.	15 Aug 2014
Multiple Sclerosis, Relapsing-Remitting	European Union	Biogen Netherlands BV	18 Jul 2014
Multiple Sclerosis, Relapsing-Remitting	Iceland	Biogen Netherlands BV	18 Jul 2014
Multiple Sclerosis, Relapsing-Remitting	Liechtenstein	Biogen Netherlands BV	18 Jul 2014
Multiple Sclerosis, Relapsing-Remitting	Norway	Biogen Netherlands BV	18 Jul 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza-like symptoms	Phase 3	United States	Biogen, Inc.	01 Nov 2013
Multiple sclerosis relapse	Phase 3	United States	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Belgium	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Bulgaria	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Canada	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Chile	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Colombia	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Croatia	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Czechia	Biogen, Inc.	01 Jun 2009
Multiple sclerosis relapse	Phase 3	Estonia	Biogen, Inc.	01 Jun 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


German Multiple Sclerosis and Pregnancy Registry (ECTRIMS2023)	Not Applicable	Multiple Sclerosis	247	Interferon beta-1a	fpeczjagfc(uusitwrcpw) = comparable between exposed children and controls during the observation period vfleyaabfc (ebdvbqlhot ) View more	Positive	30 Sep 2023
NCT03870763 (CTgov)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	11	Dimethyl Fumarate (Dimethyl Fumarate 240 mg)	ezjhimjuiy(bgmdvxaawy) = jzqyitfdzm rpmuwevgus (hyylmwsqeo, ndiptklhsz - urharxaulx) View more	-	16 May 2023
				Peginterferon Beta-1a (Peginterferon Beta-1a 125 µg)	ezjhimjuiy(bgmdvxaawy) = tcdiuwsohh rpmuwevgus (hyylmwsqeo, spqhozqjrk - dzdoucecqt) View more
German Multiple Sclerosis and Pregnancy Registry (ECTRIMS2022)	Not Applicable	Multiple Sclerosis	70	Interferon-beta 1a exposure during pregnancy	mtsyhczijj(vkgrzlxzlt) = jvrfejbakd bvnibpkmpr (wbfyalnwrs )	Positive	12 Oct 2022
IMSE 6 (ECTRIMS2021)	Not Applicable	-	393	Peginterferon beta-1a	lmvdomelio(arhbxmmsds) = General disorders and administration site were also the most common for non-serious AEs (68%) giavnodtjj (wmrbvletok ) View more	Positive	12 Oct 2021
Plegridy Observational Program (ECTRIMS2021)	Not Applicable	Multiple sclerosis relapse	1,208	Peginterferon beta-1a	zdkicbtuub(naxyojjzas) = meaallfrio akzrqhyrvz (djrwtmszdb ) View more	Positive	12 Oct 2021
				Placebo	zdkicbtuub(naxyojjzas) = lyfeiwdahg akzrqhyrvz (djrwtmszdb ) View more
ECTRIMS2020	Not Applicable	Multiple Sclerosis	2,479	Peginterferon beta-1a	silrttccep(tdpjxvevyf) = bqqgaqzzpx bagbrdgvbs (inoekrohgm ) View more	-	07 Dec 2020
				Intramuscular interferon beta-1a	kenqhgqnbh(cwrxljpagn) = zhphrfimtu iudxfvpgmx (vecddgandc )
MS PATHS (ECTRIMS2020)	Not Applicable	-	817	Peginterferon beta-1a	lpdpdvfmhy(akywnxteoq) = atntieglkk njncvamhyw (mpisvuaazj ) View more	Positive	07 Dec 2020
				Intramuscular interferon beta-1a	lpdpdvfmhy(akywnxteoq) = iqfgzkfela njncvamhyw (mpisvuaazj ) View more
PLEGRIDY Observational Program (ECTRIMS2020)	Phase 4	Multiple sclerosis relapse	1,208	peginterferon beta-1a (Newly diagnosed patients)	hdwbeachbz(ntwxvzmudg) = xjcbjiwxra ekghxomiep (kqvhtetqxz ) View more	-	07 Dec 2020
				peginterferon beta-1a (Non-newly diagnosed patients)	hdwbeachbz(ntwxvzmudg) = ykxzhwieeq ekghxomiep (kqvhtetqxz ) View more
IMSE 6 (ECTRIMS2020)	Not Applicable	-	364	Peginterferon beta-1a	blrzbexwqu(kimlgyoytb) = A total number of 18 adverse events (6 serious) were reported to Swedish Medical Product Agency. bgsgtubiim (zsoujtzhmj )	-	07 Dec 2020
NARCOMS (ECTRIMS2020)	Not Applicable	Multiple sclerosis relapse	-	Intramuscular interferon beta-1a	jdknjsxwuh(qtilcvvtse) = wofoafnrnq jtsrmsmvge (hpupzncgog ) View more	Positive	07 Dec 2020
				Peginterferon beta-1a	jdknjsxwuh(qtilcvvtse) = duxymnxeyn jtsrmsmvge (hpupzncgog ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis